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Abstract  42 
Background 43 
Haematological malignancy is an important cause of pleural effusion. Pleural 44 
effusions secondary to haematological malignancy are usually lymphocyte 45 
predominant. However, several other conditions such as carcinoma, tuberculosis 46 
and chronic heart failure also cause lymphocytic effusions. Lymphocyte subset 47 
analysis may be a useful test to identify haematological malignancy in patients with 48 
lymphocytic effusions. However, research into their utility in pleural effusion 49 
diagnostic algorithms has not yet been published. 50 
Objectives 51 
We aimed to determine the clinical utility of pleural fluid lymphocyte subset 52 
analysis, and whether it can be applied to a diagnostic algorithm to identify effusions 53 
secondary to haematological malignancy. The secondary aim was to evaluate the 54 
diagnostic value of pleural fluid differential cell count.  55 
Methods 56 
Consecutive consented patients presenting to our pleural service between 57 
2008-2013 underwent thoracentesis and differential cell count analysis. We 58 
proposed an algorithm which selected patients with lymphocytic effusions (>50%) to 59 
have further fluid sent for lymphocyte subset analysis. Two independent consultants 60 
agreed the cause of the original effusion after a 12-month follow-up period. 61 
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Results 62 
60 patients had samples sent for lymphocyte subset analysis. Lymphocyte 63 
subset analysis had an 80% sensitivity (8/10) and a 100% specificity for the 64 
diagnosis of haematological malignancy. The positive and negative predictive values 65 
were 100% and 96.1% respectively. 344 differential cell counts were analysed; 16% 66 
of pleural effusions with a malignant aetiology were neutrophilic or eosinophilic at 67 
presentation. A higher neutrophil and eosinophil count was associated with benign 68 
diagnoses whereas a higher lymphocyte count was associated with malignant 69 
diagnoses. 70 
Conclusions 71 
Lymphocyte subset analysis may identify haematological malignancy in a 72 
specific cohort of patients with undiagnosed pleural effusions. A pleural fluid 73 
differential cell count provides useful additional information to streamline patient 74 
pathway decisions.  75 
List of abbreviations 76 
 77 
AF  Atrial fibrillation 78 
BAPE  Benign asbestos related pleural effusion 79 
CABG  Coronary artery bypass graft 80 
CLL  Chronic lymphocytic leukaemia 81 
DLCBL Diffuse large cell B-Lymphoma 82 
HIV  Human immunodeficiency virus 83 
HTN  Hypertension 84 
IHD  Ischaemic heart disease,  85 
LS  Lymphocyte subset 86 
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NHL  Non-Hodgkin’s lymphoma 87 
T2DM  Type 2 Diabetes Mellitus  88 
TB  Tuberculosis  89 
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Introduction 90 
Haematological cancers are amongst the commonest causes of a malignant 91 
pleural effusion[1, 2]. Up to 16% of patients with Hodgkin and Non-Hodgkin 92 
Lymphoma will have a pleural effusion during their illness, occurring as either a 93 
presenting feature or later on in the disease course[3, 4]. The mechanisms of pleural 94 
effusion include pleural infiltration by the tumour, lymphatic obstruction, secondary 95 
heart failure, renal failure and hypoalbuminaemia [5]. Historically, the diagnosis of 96 
pleural involvement in haematological malignancy was based on simple cytological 97 
examination of pleural fluid, however reported diagnostic rates using this method 98 
alone can be highly variable [5]. Lymphocyte subset (LS) analysis, also referred to 99 
as flow cytometry, is amongst a number of more advanced cytological tests which 100 
can improve diagnostic yield [6]. LS has been suggested as a useful investigation in 101 
pleural effusions to identify those patients with haematological malignancy, although 102 
data remains limited and there may be significant costs associated with such tests 103 
[6]. Bangerter et al looked at both ascitic and pleural fluid and found the combined 104 
use of standard cytology and LS analysis achieved a sensitivity and specificity of 105 
100% [7]. Despite this, there is currently no established guidance for clinicians as to 106 
where pleural fluid LS analysis may fit into a standard diagnostic algorithm.  107 
Traditionally, cytology reports comment upon the presence or absence of 108 
visible malignant cells. When the predominant cell type in pleural fluid is also 109 
reported, patients with haematological malignancy are typically found to have 110 
lymphocytic effusions. An accurate understanding of the cellular constituents of 111 
pleural fluid can help to improve differential diagnosis and allows targeted 112 
investigations in patients with undiagnosed pleural effusions. For example, 113 
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lymphocyte-predominant effusions are usually felt to warrant more invasive 114 
investigation, such as pleural biopsy, as the differential diagnosis includes 115 
malignancy and tuberculosis (TB) [8-10]. In contrast, neutrophilic effusions are more 116 
likely to represent an acute process such as infection [11]. 117 
The primary purpose of this study was to determine the effectiveness of a 118 
standardised algorithm, which focused on the role and utility of pleural LS analysis 119 
for those patients presenting with undiagnosed pleural effusions. As a secondary 120 
aim, we looked to investigate whether a differential cell count with a percentage 121 
breakdown of cellular constituents would provide any valuable additional clinical 122 
information.  123 
Materials and Methods 124 
The analysis utilised prospectively-collected data from patients presenting 125 
consecutively to a well-established pleural service between 2008 and 2013. Those 126 
with an undiagnosed unilateral pleural effusion were reviewed as part of a broader, 127 
actively maintained pleural database and associated study. The project received 128 
ethical approval from the South West regional ethics committee (08/H0102/11) and 129 
was registered with the UK Clinical Trials Register (UKCRN ID 8960). All patients 130 
provided informed written consent to take part in the study and have their details and 131 
samples stored.  132 
As part of their initial work-up, patients had pleural fluid sent for routine 133 
analysis, including cytology. The study protocol also called for full pleural fluid 134 
differential cell count to be reported (Fig 1). All samples were examined by 135 
experienced cytopathologists, mainly M.B. In those with previous history of 136 
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haematological malignancy at presentation or clinical picture highly suggestive of 137 
haematological malignancy (such as radiological lymphadenopathy or “B” 138 
symptoms), LS analysis of the pleural fluid was also requested at presentation.   139 
Full details of cytology reporting and LS analysis can be found in the supporting 140 
information.  Effusions with >50% neutrophils or lymphocytes were categorised as 141 
neutrophilic and lymphocytic respectively, and those with >10% eosinophils were 142 
categorised as eosinophilic. Pleural effusions could therefore be defined 143 
simultaneously as both eosinophilic and lymphocytic or neutrophilic.  144 
Figure 1. Proposed algorithm for selecting patients who require 145 
lymphocyte subset analysis. 146 
Following initial investigations, those patients with a lymphocytic effusion on 147 
cytology, but with no firm tissue diagnosis of malignancy or clear alternative 148 
diagnosis (e.g. a transudative collection in a patient with known heart failure), had a 149 
second pleural fluid sample taken (Fig 1). This second sample was sent to a specific, 150 
experienced immunologist for LS analysis, as well as for repeat cytological 151 
examination. The final diagnosis for all pleural effusions was confirmed by two 152 
independent respiratory physicians after a minimum of 12 months of follow-up (or 153 
after death). These physicians were not blinded to the LS results. All diagnoses were 154 
classified into pre-defined groups to facilitate further analysis. The full diagnostic 155 
criteria can be found in the online supporting information. In those cases where there 156 
were felt to be multiple contributing factors to a pleural effusion, the likely causes 157 
were ordered to signify the greatest contributing factor first. For the purposes of this 158 
analysis, only the primary cause was used.   159 
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Statistical analysis was carried out using Microsoft Excel (2011), SPSS 160 
Statistics (9.5.0.0) and Social Science Statistics (www.socscistatistics.com).  161 
Results  162 
Patient demographics 163 
A total of 509 patients were recruited during the study period. The most 164 
common final diagnoses were metastatic malignancy (n=188, 36.9%), infection 165 
(n=93, 18.3%), malignant mesothelioma (n=74, 14.5%) and cardiac failure (n=47, 166 
9.2%).  408 effusions were exudates, 61 transudates and 40 had insufficient 167 
information to enable classification. Haematological malignancy was responsible for 168 
14 cases of pleural effusion (2.8%) overall and 10/408 (2.5%) exudate effusions. 169 
Other diagnoses made up the remaining 93 cases (Table 1). 170 
The clinical utility of lymphocyte subset analysis 171 
 172 
Pleural fluid differential cell count identified 145 patients with a lymphocytic effusion. 173 
These patients were eligible to begin the diagnostic algorithm as described above, 174 
with the outcomes demonstrated in Figure 2. During initial investigations, non-175 
haematological malignancy was confirmed via cytology or biopsy in 56 patients, and 176 
a further 33 had a clear alternative diagnosis. One patient had a haematological 177 
malignancy confirmed at this stage by biopsy at bronchoscopy. There were therefore 178 
55 patients who were eligible for LS analysis on repeat pleural fluid samples. Three 179 
samples were not sent for analysis or were lost in transit.  180 
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After follow-up review, the main causes for the lymphocytic effusions were 181 
metastatic malignancy (n=58/145, 40.0%), cardiac failure (n=16/145, 11.0%), benign 182 
asbestos related pleural effusion (n=13/145, 9.0%), inflammatory pleuritis (n=12/145, 183 
8.3%), malignant mesothelioma (n=12/145, 8.3%), infection (n=10/145, 6.9%) and 184 
haematological malignancy (n=10/145, 6.9%). 185 
8/199 patients with non-lymphocyte predominant effusions had lymphocyte 186 
subsets analysed because of previous history of haematological malignancy or 187 
MGUS (myoclonal gammopathy of unknown significance) or clinical features strongly 188 
suggestive of haematological malignancy. 1 of these patients was subsequently 189 
diagnosed with an effusion secondary to diffuse large B cell lymphoma. In this case 190 
the differential cell count showed predominantly mesothelial cells and macrophages 191 
rather than a lymphocytosis. The remaining 7 had alternative diagnoses; 3 non-192 
haematological malignancy, 3 malignant mesothelioma and 1 congestive heart 193 
failure.  194 
Figure 2. Diagnostic algorithm outcomes for 509 patients presenting with 195 
a unilateral pleural effusion  196 
MGUS = Monoclonal gammopathy of unknown significance, TB = Tuberculosis  197 
Haematological malignancy was ultimately diagnosed in 10/145 (6.9%) patients 198 
with a lymphocytic effusion, comprising eight non-Hodgkin’s lymphoma (of which 199 
three were diffuse large B cell lymphoma and one was Burkitt’s lymphoma) and two 200 
chronic lymphocytic leukaemia. 1/10 patients were diagnosed by biopsy without LS 201 
analysis (as mentioned previously).  202 
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In total, ten patients (10/60, 16.7%) with LS analysis performed had an effusion 203 
secondary to haematological malignancy. 4 patients did not undergo lymphocyte 204 
subset analysis but had a subsequent diagnosis of haematological malignancy. In 205 
these cases the patients had symptoms, signs and radiological features to suggest 206 
haematological malignancy at presentation. The patients therefore had alternative 207 
investigations to confirm their diagnosis such as lymph node and/or bronchoscopy 208 
biopsy. Full patient details can be found in Table 2.  209 
LS analysis was diagnostic for haematological malignancy in 8/10 patients. 210 
Diagnostic confirmation was subsequently obtained in 9/10 patients whereby other 211 
tissue was biopsied or other fluid (ascitic/blood) sent for subset analysis.  212 
Lymphocyte subset analysis had a sensitivity of 80% and a specificity of 100% 213 
for the diagnosis of haematological malignancy (95% confidence intervals 44-96% 214 
and 91-100% respectively). The positive (PPV) and negative (NPV) predictive values 215 
were 100% (95% confidence interval 60-100%) and 96.1% (95% confidence interval 216 
86-99%) respectively. In the two patients with non-diagnostic lymphocytic effusions 217 
diagnosis was made by bone marrow and lymph node biopsy.  218 
A differential cell count confers additional useful clinical 219 
information 220 
A differential cell count was available for 344/509 patients as 165 patients had 221 
an unsatisfactory sample. Of these, as described above, there were 145 patients 222 
with >50% lymphocytes, 54 with >10% eosinophils and 48 with >50% neutrophils. 23 223 
patients had both lymphocytic and eosinophilic effusions. Therefore 120 effusions 224 
had a mixed cellular picture which did not fit into the aforementioned categories. 225 
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These included combinations of macrophages, neutrophils, lymphocytes, 226 
eosinophils, malignant and mesothelial cells.  227 
The main diagnoses of patients with lymphocytic effusions have been set out 228 
above. The main diagnoses in the 54 patients with an eosinophilic effusion were; 229 
metastatic malignancy (n=20/54, 37.0%), malignant mesothelioma (n=8/54, 14.8%), 230 
pleural infection (n=7/54, 13.0%) and benign asbestos related pleural effusion 231 
(n=6/54, 11.1%). The main diagnoses in 48 patients with a neutrophilic effusion 232 
were; pleural infection (n=36/48, 75.0%), metastatic malignancy (n=6/48, 12.5%) and 233 
malignant mesothelioma (n=5/48, 10.4%). 234 
The frequencies of benign and malignant effusions by cell type are set out in 235 
Table 3. Chi-squared comparison produces a p-value of <0.05.  236 
Table 3. The frequency of benign and malignant effusions of 344 patients with 237 
a unilateral pleural effusion and a percentage differential cell count 238 
187 patients with a malignant pleural effusion (including metastatic malignancy, 239 
mesothelioma and haematological malignancy) had a differential cell count available 240 
(Fig 3).  241 
Figure 3. Differential cell count of 187 patients with a pleural effusion 242 
secondary to malignancy. 243 
A benign diagnosis was found in 12/16 effusions with >30% eosinophils 244 
compared to 15/25 of effusions with values between 10 and 20%. Highly neutrophilic 245 
effusions were more likely to be benign. However 23% (7/30) of effusions with >80% 246 
neutrophils were associated with malignancy. A higher lymphocyte count was 247 
associated with malignancy as effusions with >80% lymphocytes had a 63.4% 248 
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(26/41) chance of being malignant. One patient with an eosinophilic effusion had a 249 
traumatic haemothorax.    250 
Of those patients with pleural infection and a lymphocytic effusion 6/10 patients 251 
had experienced symptoms for two or more weeks. Additionally, 3/10 had a 252 
concurrent diagnosis of cardiac failure, one patient had a concurrent diagnosis of 253 
malignancy and one patient was infected with mycobacterium avium. Of the 16 254 
patients with >90% lymphocytes 75% (n=12) had effusions that were caused by 255 
malignancy.  256 
Discussion 257 
Targeted lymphocyte subset analysis 258 
This is the first study to prospectively analyse the use of LS exclusively in 259 
unilateral pleural effusions. In our study population, haematological malignancy was 260 
responsible for 14 pleural effusions. This relatively small incidence, coupled with the 261 
time and labour intensive nature of LS analysis, makes it impractical to be applied to 262 
all undiagnosed effusions. There are currently limited data exploring the clinical utility 263 
of routine lymphocyte subset analysis, with the most recent national guidelines 264 
unable to propose how LS analysis should be incorporated into the investigation 265 
algorithm for undiagnosed pleural effusions [6]. Those studies which have previously 266 
looked at the utility of LS analysis have not focussed specifically on pleural effusions 267 
[7, 12].  268 
Our targeted algorithm was designed to restrict LS analysis to those patients 269 
with a previous history of haematological malignancy, or with undiagnosed 270 
lymphocytic effusions. This ensured that the test remained practical in day-to-day 271 
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clinical use and was only applied to a group who were felt to be most likely to benefit 272 
from repeat sampling. We were able to demonstrate high sensitivity and specificity 273 
for the diagnosis of haematological malignancy, at 80% and 100% respectively. This 274 
suggests that there may be a place for the addition of LS in the routine diagnostic 275 
pathway for new pleural effusions. By following this approach, LS analysis was only 276 
required in 60/509 (11.8%) patients presenting to our service during the study period, 277 
suggesting it may be applied in a relatively selective manner. 278 
In our centre differential cell count results are not usually available for 48 hours 279 
post-thoracentesis by which time sample degradation rules out adequate LS 280 
analysis. However, if this result could be obtained more rapidly it may allow for 281 
targeted LS analysis on the first thoracentesis sample avoiding the need for a 282 
second procedure. We would suggest that individual centres could alter the 283 
algorithm according to their local service provision.  284 
In patients who had lymphocyte subset analysis performed without a 285 
lymphocyte predominant effusion 1/8 had haematological malignancy confirmed as 286 
the cause of their effusion. Further research is required to determine whether 287 
lymphocyte subset analysis is indicated within this group.  288 
Differential cell count aids diagnosis 289 
Standard practice in differential cell count reporting is to provide a cellular 290 
description or predominant cell type. Our work has indicated that a specific 291 
percentage differential cell count can provide useful clinical information, helping to 292 
narrow the differential diagnosis at presentation and potentially alter management 293 
pathways.  294 
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It has previously been reported that highly neutrophilic or eosinophilic effusions 295 
are pathognomic of benign processes [11, 13]. However, our data suggest an 296 
effusion with >80% neutrophils has a one in four chance of having an underlying 297 
malignant aetiology. Whilst we found that highly eosinophilic effusions were less 298 
likely to be malignant, in one case we found eosinophil counts of up to 65% in a 299 
malignant effusion. Overall we found that 16% of malignant pleural effusions in this 300 
series were neutrophilic or eosinophilic. It must therefore be stressed that highly 301 
neutrophilic or eosinophilic effusions are not always associated with a benign 302 
aetiology. One patient in this series with a eosinophilic effusion had a traumatic 303 
haemothorax, although the presence of eosinophils in pleural fluid has previously 304 
been shown to be associated with air or blood in the pleural space[14].  305 
Lymphocytic effusions often raise diagnostic concern, especially regarding the 306 
presence of malignancy. Indeed, malignancy and TB have been reported to be the 307 
cause of around two thirds of lymphocytic effusions in areas of moderate TB 308 
prevalence [15]. In our patient population, the prevalence of TB was much lower, 309 
with just 10/509 patients diagnosed, 6 of whom had lymphocytic effusions. Studies 310 
have previously suggested several causes of an effusion with >80% lymphocytes 311 
including lymphoma, rheumatoid, post-coronary artery bypass graft (CABG), 312 
malignancy and TB [9]. Lymphocytes are also known to predominate in longstanding 313 
effusions of over 2 weeks duration.  314 
We have also suggested potential benefit in knowing the percentage of 315 
lymphocytes in those with lymphocytic effusions. We found that with increasing 316 
lymphocyte percentages, the likelihood of malignancy rose. Patients with highly 317 
lymphocytic effusions, in the right clinical context, should therefore be routinely 318 
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considered for tissue biopsy via image guided techniques or thoracoscopy, as well 319 
as for lymphocyte subset analysis. 320 
Limitations 321 
There are a number of limitations to our study. The primary limitation is the small 322 
number of patients with pleural effusions caused by haematological malignancy, 323 
which LS analysis is intended to detect, although the proportions found in our cohort 324 
overall are similar to those in other large scale studies [16]. Additionally, there will 325 
always remain a group of patients in which LS analysis may be appropriate 326 
regardless of the proposed algorithm, and these must be addressed on a case-by-327 
case basis. Examples of these might be patients with significant undiagnosed 328 
lymphadenopathy, classical symptoms and signs of haematological malignancy, or 329 
non-specifically suspicious cytology. In our study four patients were found to have 330 
haematological malignancy causing a pleural effusion and were not accommodated 331 
by the proposed algorithm.  332 
It could also be argued that the 16.7% of patients who had the test performed 333 
and who went on to be confirmed as having a haematological malignancy, is too low 334 
a proportion to justify its routine clinical use. Whilst clearly not ideal, we feel the 335 
selection of patients based upon the finding of lymphocyte-predominant fluid is the 336 
only approach which can practicably be applied to the current investigation pathways 337 
for those presenting with undiagnosed effusions. 338 
Although our study focussed on the role of lymphocytes, neutrophils and 339 
eosinophils in pleural effusions, there are several cell types which were not present 340 
in large enough numbers frequently enough to comment upon in this series. It has 341 
been suggested previously that effusions with >10% basophils have an increased 342 
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risk of leukaemia and are also associated with pneumothoraces and pneumonias 343 
[17, 18]. The presence of macrophages in effusions is generally thought to be non-344 
diagnostic as they are difficult to distinguish from mesothelial cells due to 345 
overlapping morphological characteristics [17, 19]. As mentioned above, the 346 
presence of air or blood in the pleural space has been associated with eosinophilic 347 
effusions[14]. The results presented here represent the first thoracentesis procedure 348 
carried out by the study group, however a small number of patients may have 349 
undergone thoracentesis at a different centre prior to presentation to our pleural 350 
service, which may account for a minority of eosinophilic effusions.   351 
A large number of patients (165/509) in our study had unsuitable pleural fluid 352 
samples and did not go on to have a differential cell count. In these patients samples 353 
were either predominantly blood or had too few cells to enable sufficient analysis. 354 
Within the 165 patients with no differential cell count the major diagnoses were; 355 
metastatic malignancy (n=53/165, 32.1%, malignant mesothelioma (n=34/165, 356 
20.6%) and pleural infection (n=31/165, (18.8%). The high proportion of malignancy 357 
here should reiterate the need for further investigation of this patient cohort. Despite 358 
this, 344 patients had a differential cell count reported and analysed. 359 
Whilst the study participants were prospectively recruited to the study the 360 
algorithm was retrospectively applied to the cohort. The participants were recruited 361 
as part of a part of a wider study described in the “Materials and Methods”. 362 
9/10 patients with haematological malignancy who had lymphocyte subset 363 
analysis in this study also required additional biopsy or investigation to confirm the 364 
diagnosis (Table 2). We would suggest LS analysis diagnosed the cause of the 365 
effusion and the disease was subsequently confirmed on further investigation. 366 
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Further confirmation was required to enable haematologists to make appropriate 367 
decisions regarding the treatment of the haematological malignancy. 368 
Conclusions 369 
Lymphocyte subset analysis appears to have a high sensitivity and specificity 370 
for the identification of haematological malignancy as a cause of pleural effusion in 371 
those with lymphocyte predominant effusions. A differential cell count can help to 372 
guide further investigation and is helpful in the diagnosis of undiagnosed unilateral 373 
pleural effusions. Furthermore, a neutrophil or eosinophil predominant effusion is not 374 
always an indicator of a benign process. In addition to this, a higher percentage of 375 
pleural fluid lymphocytosis is associated with a malignant aetiology. Patients with a 376 
lymphocytic pleural effusion and no obvious alternative diagnosis after initial testing 377 
may benefit from repeat fluid sampling and lymphocyte subset analysis. In order to 378 
confirm the clinical utility of our proposed algorithm, further prospective analysis 379 
including a greater number of patients with effusions secondary to haematological 380 
malignancy will be required.  381 
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